All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Advaxis Inc., of North Brunswick, N.J., received approval from the data safety monitoring board to dose remaining patients in its trial of ADXS11-001 immunotherapy in cervical dysplasia.
